

**LIPOSOME PHARMACEUTICAL****Publication number:** JP61271204**Publication date:** 1986-12-01**Inventor:** KANEKI HIROYUKI; YAMAGUCHI MICHIIRO;  
MACHIDA YASUHIKO; AKIYASU AKIRA**Applicant:** SHISEIDO CO LTD**Classification:****- international:** **A61K8/30; A61K8/11; A61K8/14; A61K9/00;**  
**A61K9/127; A61K8/30; A61K8/11; A61K8/14;**  
**A61K9/00; A61K9/127; (IPC1-7): A61K7/00; A61K9/00****- European:** A61K9/127B; A61K9/127**Application number:** JP19850112039 19850527**Priority number(s):** JP19850112039 19850527[Report a data error here](#)**Abstract of JP61271204**

**PURPOSE:**A liposome pharmaceutical, obtained by embedding a hydroquinone glycoside on a lamella phase of a complex lipid, and incorporating sterol as a stabilizer therein and having improved stability and selective migration to the affected part of the hydroquinone glycoside and further sustained release properties. **CONSTITUTION:**A liposome pharmaceutical obtained by embedding a hydroquinone glycoside expressed by the formula (R is residue, e.g. L-arabinose) in a lamella phase of a complex lipid, e.g. natural or synthetic phospholipid, at 1:0.2-0.7 weight ratio of the former to the latter, and incorporating sterol, e.g. cholesterol or beta-sitosterol, as a stabilizer therein. A charge is desirably imparted to the lamella phase of the complex lipid for enhancing the dispersion stability of the liposome. When a negative charge is imparted, a lipid, e.g. phosphatidyl serine or dicetyl phosphate, having the negative charge is incorporated. When a positive charge is imparted, a lipid, e.g. stearylamine, having the positive charge is incorporated.

© 2006 Esp@Cenet, a division of Esp@Cenet Ltd. All rights reserved.Data supplied from the **esp@cenet** database - Worldwide